Skip to main content
Top
Published in: Respiratory Research 1/2007

Open Access 01-12-2007 | Research

Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke

Authors: Ruth E MacRedmond, Catherine M Greene, Delbert R Dorscheid, Noel G McElvaney, Shane J O'Neill

Published in: Respiratory Research | Issue 1/2007

Login to get access

Abstract

The toll-like receptors (TLRs) are a key component of host defense in the respiratory epithelium. Cigarette smoking is associated with increased susceptibility to infection, while COPD is characterised by bacterial colonisation and infective exacerbations. We found reduced TLR4 gene expression in the nasal epithelium of smokers compared with non-smoking controls, while TLR2 expression was unchanged. Severe COPD was associated with reduced TLR4 expression compared to less severe disease, with good correlation between nasal and tracheal expression. We went on to examine the effect of potential modulators of TLR4 expression in respiratory epithelium pertinent to airways disease. Using an airway epithelial cell line, we found a dose-dependent downregulation in TLR4 mRNA and protein expression by stimulation with cigarette smoke extracts. Treatment with the corticosteroids fluticasone and dexamethasone resulted in a dose-dependent reduction in TLR4 mRNA and protein. The functional significance of this effect was demonstrated by impaired IL-8 and HBD2 induction in response to LPS. Stimulation with salmeterol (10-6 M) caused upregulation of TLR4 membrane protein presentation with no upregulation of mRNA, suggesting a post-translational effect. The effect of dexamethasone and salmeterol in combination was additive, with downregulation of TLR4 gene expression, and no change in membrane receptor expression. Modulation of TLR4 in respiratory epithelium may have important implications for airway inflammation and infection in response to inhaled pathogens.
Literature
1.
go back to reference Strieter RM, Belperio JA, Keane MP: Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis 2003, 16:193–198.CrossRefPubMed Strieter RM, Belperio JA, Keane MP: Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis 2003, 16:193–198.CrossRefPubMed
2.
go back to reference Diamond G, Legarda D, Ryan LK: The innate immune response of the respiratory epithelium. Immunol Rev 2000, 173:27–38.CrossRefPubMed Diamond G, Legarda D, Ryan LK: The innate immune response of the respiratory epithelium. Immunol Rev 2000, 173:27–38.CrossRefPubMed
3.
go back to reference MacRedmond R, Greene C, Taggart CC, McElvaney N, O'Neill S: Respiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharide. Respir Res 2005, 6:116.CrossRefPubMedPubMedCentral MacRedmond R, Greene C, Taggart CC, McElvaney N, O'Neill S: Respiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharide. Respir Res 2005, 6:116.CrossRefPubMedPubMedCentral
4.
go back to reference Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB Jr.: Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A 1998, 95:14961–14966.CrossRefPubMedPubMedCentral Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB Jr.: Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A 1998, 95:14961–14966.CrossRefPubMedPubMedCentral
5.
go back to reference Global Initiative for Chronic Obstructive Lung Disease www.gold.com: Global Initiative for Chronic Obstructive Lung Disease www.gold.com:
7.
go back to reference Sethi S, Murphy TF: Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001, 14:336–363.CrossRefPubMedPubMedCentral Sethi S, Murphy TF: Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001, 14:336–363.CrossRefPubMedPubMedCentral
8.
go back to reference Bridges MA, Walker DC, Davidson AG: Cystic fibrosis and control nasal epithelial cells harvested by a brushing procedure. In Vitro Cell Dev Biol 1991, 27A:684–686.CrossRefPubMed Bridges MA, Walker DC, Davidson AG: Cystic fibrosis and control nasal epithelial cells harvested by a brushing procedure. In Vitro Cell Dev Biol 1991, 27A:684–686.CrossRefPubMed
9.
go back to reference Kelsen SG, Mardini IA, Zhou S, Benovic JL, Higgins NC: A technique to harvest viable tracheobronchial epithelial cells from living human donors. Am J Respir Cell Mol Biol 1992, 7:66–72.CrossRefPubMed Kelsen SG, Mardini IA, Zhou S, Benovic JL, Higgins NC: A technique to harvest viable tracheobronchial epithelial cells from living human donors. Am J Respir Cell Mol Biol 1992, 7:66–72.CrossRefPubMed
10.
go back to reference Laurent P, Janoff A, Kagan HM: Cigarette smoke blocks cross-linking of elastin in vitro. Chest 1983, 83:63S-65S.CrossRefPubMed Laurent P, Janoff A, Kagan HM: Cigarette smoke blocks cross-linking of elastin in vitro. Chest 1983, 83:63S-65S.CrossRefPubMed
11.
go back to reference Bateman RM, Tokunaga C, Kareco T, Dorscheid DR, Walley KR: Myocardial hypoxia-inducible HIF-1alpha, VEGF, and GLUT1 gene expression is associated with microvascular and ICAM-1 heterogeneity during endotoxemia. Am J Physiol Heart Circ Physiol 2007, 293:H448–56.CrossRefPubMed Bateman RM, Tokunaga C, Kareco T, Dorscheid DR, Walley KR: Myocardial hypoxia-inducible HIF-1alpha, VEGF, and GLUT1 gene expression is associated with microvascular and ICAM-1 heterogeneity during endotoxemia. Am J Physiol Heart Circ Physiol 2007, 293:H448–56.CrossRefPubMed
12.
go back to reference Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'Neill S J, McElvaney NG: TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 2005, 174:1638–1646.CrossRefPubMed Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'Neill S J, McElvaney NG: TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol 2005, 174:1638–1646.CrossRefPubMed
13.
go back to reference Homma T, Kato A, Hashimoto N, Batchelor J, Yoshikawa M, Imai S, Wakiguchi H, Saito H, Matsumoto K: Corticosteroid and cytokines synergistically enhance TLR2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004. Homma T, Kato A, Hashimoto N, Batchelor J, Yoshikawa M, Imai S, Wakiguchi H, Saito H, Matsumoto K: Corticosteroid and cytokines synergistically enhance TLR2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004.
14.
go back to reference Hubner M, Hochhaus G, Derendorf H: Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005, 25:469–488.CrossRefPubMed Hubner M, Hochhaus G, Derendorf H: Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005, 25:469–488.CrossRefPubMed
15.
go back to reference Sarir H, Mortaz E, Karimi K, Johnson M, Nijkamp FP, Folkerts G: Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages. Eur J Pharmacol 2007, 571:55–61.CrossRefPubMed Sarir H, Mortaz E, Karimi K, Johnson M, Nijkamp FP, Folkerts G: Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages. Eur J Pharmacol 2007, 571:55–61.CrossRefPubMed
16.
go back to reference Oltmanns U, Walters M, Sukkar M, Xie S, Issa R, Mitchell J, Johnson M, Chung KF: Fluticasone, but not salmeterol, reduces cigarette smoke-induced production of interleukin-8 in human airway smooth muscle. Pulm Pharmacol Ther 2007. Oltmanns U, Walters M, Sukkar M, Xie S, Issa R, Mitchell J, Johnson M, Chung KF: Fluticasone, but not salmeterol, reduces cigarette smoke-induced production of interleukin-8 in human airway smooth muscle. Pulm Pharmacol Ther 2007.
18.
go back to reference Qvarfordt I, Riise GC, Andersson BA, Larsson S: Lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations. Respir Med 2000, 94:881–887.CrossRefPubMed Qvarfordt I, Riise GC, Andersson BA, Larsson S: Lower airway bacterial colonization in asymptomatic smokers and smokers with chronic bronchitis and recurrent exacerbations. Respir Med 2000, 94:881–887.CrossRefPubMed
19.
go back to reference Zalacain R, Sobradillo V, Amilibia J, Barron J, Achotegui V, Pijoan JI, Llorente JL: Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999, 13:343–348.CrossRefPubMed Zalacain R, Sobradillo V, Amilibia J, Barron J, Achotegui V, Pijoan JI, Llorente JL: Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999, 13:343–348.CrossRefPubMed
20.
go back to reference Graham NM: The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol Rev 1990, 12:149–178.PubMed Graham NM: The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol Rev 1990, 12:149–178.PubMed
21.
go back to reference Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999, 116:40–46.CrossRefPubMed Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999, 116:40–46.CrossRefPubMed
22.
go back to reference Beisswenger C PJ Koczulla R, Seifart C, Vogelmeier C, Bals R.: Cigarette smoke alters the inflammatory reaction of airway epithelium. Eur Respir J 2003, 22:561s. Beisswenger C PJ Koczulla R, Seifart C, Vogelmeier C, Bals R.: Cigarette smoke alters the inflammatory reaction of airway epithelium. Eur Respir J 2003, 22:561s.
23.
go back to reference Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B: Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005, 6:68.CrossRefPubMedPubMedCentral Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B: Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005, 6:68.CrossRefPubMedPubMedCentral
24.
go back to reference Suzuki M, Hisamatsu T, Podolsky DK: Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect Immun 2003, 71:3503–3511.CrossRefPubMedPubMedCentral Suzuki M, Hisamatsu T, Podolsky DK: Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect Immun 2003, 71:3503–3511.CrossRefPubMedPubMedCentral
25.
go back to reference Abreu MT, Thomas LS, Arnold ET, Lukasek K, Michelsen KS, Arditi M: TLR signaling at the intestinal epithelial interface. J Endotoxin Res 2003, 9:322–330.CrossRefPubMed Abreu MT, Thomas LS, Arnold ET, Lukasek K, Michelsen KS, Arditi M: TLR signaling at the intestinal epithelial interface. J Endotoxin Res 2003, 9:322–330.CrossRefPubMed
26.
go back to reference Ohashi K, Burkart V, Flohe S, Kolb H: Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000, 164:558–561.CrossRefPubMed Ohashi K, Burkart V, Flohe S, Kolb H: Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000, 164:558–561.CrossRefPubMed
27.
go back to reference Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd: The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001, 276:10229–10233.CrossRefPubMed Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd: The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001, 276:10229–10233.CrossRefPubMed
28.
go back to reference Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG: Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003, 544:129–132.CrossRefPubMed Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG: Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003, 544:129–132.CrossRefPubMed
29.
go back to reference Taggart CC, Greene CM, McElvaney NG, O'Neill S: Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002, 277:33648–33653.CrossRefPubMed Taggart CC, Greene CM, McElvaney NG, O'Neill S: Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002, 277:33648–33653.CrossRefPubMed
30.
go back to reference Greene CM, McElvaney NG, O'Neill SJ, Taggart CC: Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004, 72:3684–3687.CrossRefPubMedPubMedCentral Greene CM, McElvaney NG, O'Neill SJ, Taggart CC: Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004, 72:3684–3687.CrossRefPubMedPubMedCentral
31.
go back to reference Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, Nakanishi K, Kimoto M, Miyake K, Takeda K, Akira S: Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 2000, 164:3476–3479.CrossRefPubMed Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, Nakanishi K, Kimoto M, Miyake K, Takeda K, Akira S: Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 2000, 164:3476–3479.CrossRefPubMed
32.
go back to reference Lieberman D: Pseudomonal infections in patients with COPD: epidemiology and management. Am J Respir Med 2003, 2:459–468.CrossRefPubMed Lieberman D: Pseudomonal infections in patients with COPD: epidemiology and management. Am J Respir Med 2003, 2:459–468.CrossRefPubMed
33.
go back to reference Dowling RB, Johnson M, Cole PJ, Wilson R: Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J 1999, 14:363–369.CrossRefPubMed Dowling RB, Johnson M, Cole PJ, Wilson R: Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J 1999, 14:363–369.CrossRefPubMed
34.
go back to reference Van den Bosch JM, Westermann CJ, Aumann J, Edsbacker S, Tonnesson M, Selroos O: Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993, 14:455–459.CrossRefPubMed Van den Bosch JM, Westermann CJ, Aumann J, Edsbacker S, Tonnesson M, Selroos O: Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993, 14:455–459.CrossRefPubMed
35.
go back to reference Esmailpour N, Hogger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P: Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997, 10:1496–1499.CrossRefPubMed Esmailpour N, Hogger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P: Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997, 10:1496–1499.CrossRefPubMed
36.
go back to reference Johnson M: Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol 2002, 110:S282–90.CrossRefPubMed Johnson M: Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol 2002, 110:S282–90.CrossRefPubMed
37.
go back to reference Fransson M, Adner M, Erjefalt J, Jansson L, Uddman R, Cardell LO: Up-regulation of Toll-like receptors 2, 3 and 4 in allergic rhinitis. Respir Res 2005, 6:100.CrossRefPubMedPubMedCentral Fransson M, Adner M, Erjefalt J, Jansson L, Uddman R, Cardell LO: Up-regulation of Toll-like receptors 2, 3 and 4 in allergic rhinitis. Respir Res 2005, 6:100.CrossRefPubMedPubMedCentral
38.
go back to reference Janardhan KS, McIsaac M, Fowlie J, Shrivastav A, Caldwell S, Sharma RK, Singh B: Toll like receptor-4 expression in lipopolysaccharide induced lung inflammation. Histol Histopathol 2006, 21:687–696.PubMed Janardhan KS, McIsaac M, Fowlie J, Shrivastav A, Caldwell S, Sharma RK, Singh B: Toll like receptor-4 expression in lipopolysaccharide induced lung inflammation. Histol Histopathol 2006, 21:687–696.PubMed
39.
go back to reference Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T: Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 2002, 277:47834–47843.CrossRefPubMed Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T: Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 2002, 277:47834–47843.CrossRefPubMed
40.
go back to reference Piatti G, Ambrosetti U, Santus P, Allegra L: Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. Pharmacol Res 2005, 51:165–168.CrossRefPubMed Piatti G, Ambrosetti U, Santus P, Allegra L: Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. Pharmacol Res 2005, 51:165–168.CrossRefPubMed
41.
go back to reference Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999, 340:1948–1953.CrossRefPubMed Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999, 340:1948–1953.CrossRefPubMed
42.
go back to reference Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Bmj 2000, 320:1297–1303.CrossRefPubMedPubMedCentral Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Bmj 2000, 320:1297–1303.CrossRefPubMedPubMedCentral
43.
go back to reference Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med 2000, 343:1902–1909. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med 2000, 343:1902–1909.
44.
go back to reference Renkema TE, Schouten JP, Koeter GH, Postma DS: Effects of long-term treatment with corticosteroids in COPD. Chest 1996, 109:1156–1162.CrossRefPubMed Renkema TE, Schouten JP, Koeter GH, Postma DS: Effects of long-term treatment with corticosteroids in COPD. Chest 1996, 109:1156–1162.CrossRefPubMed
45.
go back to reference Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998, 351:773–780.CrossRefPubMed Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998, 351:773–780.CrossRefPubMed
46.
go back to reference Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775–789.CrossRefPubMed Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775–789.CrossRefPubMed
Metadata
Title
Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke
Authors
Ruth E MacRedmond
Catherine M Greene
Delbert R Dorscheid
Noel G McElvaney
Shane J O'Neill
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2007
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-8-84

Other articles of this Issue 1/2007

Respiratory Research 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.